<DOC>
	<DOCNO>NCT00707850</DOCNO>
	<brief_summary>Antiviral treatment HCV thalassemia raise concern ribavirin-induced hemolysis increase iron loading . Blood Transfusion Thalassemic patient know high risk acquire hepatitis C. The investigator try PEGASYS ( Peginterferon alpha-2a ( 40 KD ) ) plus Ribavirin Thalassemic patient HCV .</brief_summary>
	<brief_title>PegasysÂ® Plus Ribavirin Thalassemic Patients With Hepatitis C Virus Infection</brief_title>
	<detailed_description>Patients Thalassemia receive chronic blood transfusion increase prevalence chronic Hepatitis C virus ( HCV ) infection , particularly transfuse HCV serological testing become available . The investigator enrol 300 patient study . The patient receive PEGASYS ( Peginterferon alpha-2a ( 40 KD ) ) 180 microgram per week plus COPEGUS ( Ribavirin ) 1000 milligram weight less equal 75 kg 1200 milligram 75 kg 48 week . Follow period 6 month treatment . The patient visit every 4 week biochemistry lab test . The patient check quantitative HCV RNA ( Ribonucleic Acid ) third month initiation treatment assess early virologic response end study complete response rate six month treatment completion sustain response rate . The patient undetectable HCV RNA consider responder .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>HCV RNA positive Age old 12 year Ongoing pregnancy breast feed History ( Hx ) Hepatocellular Carcinoma ( HCC ) Hx alcoholic liver disease Hx bleed esophageal varix Hx hemochromatosis Hx autoimmune hepatitis Hx Suicidal attempt Hx cerebrovascular dis Hx severe retinopathy Hx severe psoriasis Hx scleroderma Hx metabolic liver disease Hx Systemic Lupus Erythematosus ( SLE )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Pegasys</keyword>
	<keyword>Ribavirin</keyword>
</DOC>